CoChat

Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer

Open access
Pécuchet, Nicolas, Laurent-Puig, Pierre, Mansuet-Lupo, Audrey, Legras, Antoine, Alifano, Marco, Pallier, Karine, Didelot, Audrey, Gibault, Laure, Danel, Claire, Just, Pierre-Alexandre, Riquet, Marc, Le Pimpec-Barthes, Françoise, Damotte, Diane, Fabre, Elisabeth, Blons, Hélène · 2017 · Oncotarget
Cited by 87

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

// Nicolas Pécuchet 1,2 , Pierre Laurent-Puig 1,3 , Audrey Mansuet-Lupo 4,5 , Antoine Legras 1 , Marco Alifano 6 , Karine Pallier 1 , Audrey Didelot 1 , Laure Gibault 7 , Claire Danel 8 , Pierre-Alexandre Just 4 , Marc Riquet 9 , Françoise Le Pimpec-Barthes 9 , Diane Damotte 4,5,* , Elisabeth Fabre 1,2,* and Hélène Blons 1,3,* 1 INSERM UMR-S1147, Paris Sorbonne Cité Université, Paris, France 2 Department of Medical Oncology, Hôpital Européen Georges Pompidou (HEGP), Assistance Publique, Hôpitaux de Paris, Paris, France 3 Department of Biochemistry, Pharmacogenetic and Molecular Oncology Unit, Hôpital Européen Georges Pompidou (HEGP), Assistance Publique, Hôpitaux de Paris, Paris, France 4 Department of Pathology, Hôpital Cochin, Assistance Publique, Hôpitaux de Paris, Paris, France 5 INSERM U1138, Paris Sorbonne Cité Université, Paris, France 6 Department of Thoracic Surgery, Hôpital Cochin, Assistance publique Hôpitaux de Paris, Paris, France 7 Department of Pathology, Hôpital Européen Georges Pompidou (HEGP), Assistance Publique, Hôpitaux de Paris, Paris, France 8 Department of Pathology, Hôpital Bichat, Assistance Publique, Hôpitaux de Paris, Paris, France 9 Department of Thoracic Surgery, Hôpital Européen Georges Pompidou (HEGP), Assistance Publique, Hôpitaux de Paris, Paris, France * These authors share senior authorship for this manuscript Correspondence: Hélène Blons, email: // Keywords : lung cancer, STK11, LKB1, isoforms, prognosis Received : July 20, 2015 Accepted : October 09, 2015 Published : November 25, 2015 Abstract STK11 is commonly mutated in lung cancer. In light of recent experimental data showing that specific STK11 mutants could acquire oncogenic activities due to the synthesis of a short STK11 isoform, we investigated whether this new classification of STK11 mutants could help refine its role as a prognostic marker. We conducted a retrospective high-throughput genotyping study in 567 resected non-squamous non-small-cell lung cancer (NSCLC) patients. STK11 exons 1 or 2 mutations (STK11 ex1-2 ) with potential oncogenic activity were analyzed separately from exons 3 to 9 (STK11 ex3-9 ). STK11 ex1-2 and STK11 ex3-9 mutations occurred in 5% and 14% of NSCLC . STK11 mutated patients were younger ( P = .01 ) and smokers ( P< .0001 ) . STK11 mutations were significantly associated with KRAS and inversely with EGFR mutations. After a median follow-up of 7.2 years (95%CI 6.8-.4), patients with STK11 ex1-2 mutation had a median OS of 24 months (95%CI 15-57) as compared to 69 months (95%CI 56-93) for wild-type (log-rank, P = .005 ) and to 91 months (95%CI 57-unreached) for STK11 ex3-9 mutations ( P = .003 ). In multivariate analysis, STK11 ex1-2 mutations remained associated with a poor prognosis ( P = .002 ). Results were validated in two public datasets. Western blots showed that STK11 ex1-2 mutatedtumors expressed short STK11 isoforms. Finally using mRNAseq data from the TCGA cohort, we showed that a stroma-derived poor prognosis signature was enriched in STK11 ex1-2 mutated tumors. All together our results show that STK11 ex1-2 mutations delineate an aggressive subtype of lung cancer for which a targeted treatment through STK11 inhibition might offer new opportunities.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.6379

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

Metadata

Authors
Pécuchet, N., Laurent-Puig, P., Mansuet-Lupo, A., Legras, A., Alifano, M., Pallier, K., Didelot, A., Gibault, L., Danel, C., Just, P.-A., Riquet, M., Le Pimpec-Barthes, F., Damotte, D., Fabre, E., & Blons, H.
Venue
Oncotarget
Published
2015-11-25
Volume
8
Issue
14
Pages
23831-23840
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2188278098
Cited by
87
References
7
FWCI
4.04
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.